Back to Search
Start Over
Novartis radioligand therapy Lutathera(r) FDA approved for pediatric patients
- Source :
- Plus Company Updates. April 24, 2024
- Publication Year :
- 2024
-
Abstract
- Basel: Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera(r) (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.792553431